PEDIATRICS Vol. 97 No. 1 January 1996, pp. 1-6
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation

A Multicenter, Randomized Trial Comparing Synthetic Surfactant With Modified Bovine Surfactant Extract in the Treatment of Neonatal Respiratory Distress Syndrome

Vermont-Oxford Neonatal Network

Objective. To compare the efficacy of a synthetic surfactant (Exosurf Neonatal, Burroughs-Wellcome Co) and a modified bovine surfactant extract (Survanta, Ross Laboratories) in the treatment of neonatal respiratory distress syndrome (RDS).

Design. Multicenter, randomized trial.

Setting. Thirty-eight neonatal intensive care units participating in the Vermont-Oxford Neonatal Network.

Patients. Premature infants (n = 1296) weighing 501 to 1500 g with RDS requiring assisted ventilation with 30% oxygen or more were enrolled within 6 hours of birth.

Interventions. Infants were randomly assigned to receive up to four intratracheal doses of the synthetic surfactant (Exosurf Neonatal, n=644) or the modified bovine surfactant extract (Survanta, n 652).

Main Outcome Measure. The primary outcome measure was the occurrence of death or chronic lung disease 28 days after birth.

Results. Death or chronic lung disease occurred in 57% of the infants treated with Exosurf Neonatal and in 54% of those infants treated with Survanta (relative risk [RR], 0.95; 95% confidence interval [CI], 0.86 to 1.04). Infants with birth weights of 1001 to 1500 g who received Survanta a had a significantly lower risk of chronic lung disease or death at 28 days (Survanta, 27% vs Exosurf, 34%; RR, 0.78; 95% CI, 0.60 to 0.99). Treatment with Survanta led to significant improvement in several secondary outcome measures. Survanta-treated infants received less supplemental oxygen and had lower mean airway pressure 6 and 72 hours after treatment. Survanta-treated infants had significantly fewer pneumothoraces (Survanta, 9% vs Exosurf, 15%; RR, 0.60; 95% CI, 0.44 to 0.81). There were no differences between the groups in the incidence of other neonatal complications.

Conclusion. Although no differences were noted between Survanta- and Exosurf-treated infants regarding the primary outcome of death or chronic lung disease at 28 days of age, the significant improvement in secondary clinical outcomes suggests that Survanta is more effective than Exosurf Neonatal in the treatment of established RDS.

Submitted on June 30, 1995
Accepted on August 21, 1995




This article has been cited by other articles:


Home page
 PediatricsHome page
W. A. Engle and and the Committee on Fetus and Newborn
Surfactant-Replacement Therapy for Respiratory Distress in the Preterm and Term Neonate
Pediatrics, February 1, 2008; 121(2): 419 - 432.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
F. Moya, S. Sinha, J. Gadzinowski, R. D'Agostino, R. Segal, C. Guardia, J. Mazela, G. Liu, and on behalf of the SELECT and STAR Study Investigato
One-Year Follow-up of Very Preterm Infants Who Received Lucinactant for Prevention of Respiratory Distress Syndrome: Results From 2 Multicenter Randomized, Controlled Trials
Pediatrics, June 1, 2007; 119(6): e1361 - e1370.
[Abstract] [Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
M. Ghodrat
Lung surfactants.
Am. J. Health Syst. Pharm., August 15, 2006; 63(16): 1504 - 1521.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
B. T. Bloom, R. H. Clark, and for the Infasurf Survanta Clinical Trial Group
Comparison of Infasurf (Calfactant) and Survanta (Beractant) in the Prevention and Treatment of Respiratory Distress Syndrome
Pediatrics, August 1, 2005; 116(2): 392 - 399.
[Abstract] [Full Text] [PDF]

Home page
 RadioGraphicsHome page
G. A. Agrons, S. E. Courtney, J. T. Stocker, and R. I. Markowitz
From the Archives of the AFIP: Lung Disease in Premature Neonates: Radiologic-Pathologic Correlation
RadioGraphics, July 1, 2005; 25(4): 1047 - 1073.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
F. R. Moya, J. Gadzinowski, E. Bancalari, V. Salinas, B. Kopelman, A. Bancalari, M. K. Kornacka, T. A. Merritt, R. Segal, C. J. Schaber, et al.
A Multicenter, Randomized, Masked, Comparison Trial of Lucinactant, Colfosceril Palmitate, and Beractant for the Prevention of Respiratory Distress Syndrome Among Very Preterm Infants
Pediatrics, April 1, 2005; 115(4): 1018 - 1029.
[Abstract] [Full Text] [PDF]

Home page
 CLIN PEDIATRHome page
J. L. Boone, M. K. Hostetter, and C. Cohen Weitzman
The Predictive Accuracy of Pre-Adoption Video Review in Adoptees from Russian and Eastern European Orphanages
Clinical Pediatrics, September 1, 2003; 42(7): 585 - 590.
[Abstract] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
D. M. King, Z. Wang, H. J. Palmer, B. A. Holm, and R. H. Notter
Bulk shear viscosities of endogenous and exogenous lung surfactants
Am J Physiol Lung Cell Mol Physiol, February 1, 2002; 282(2): L277 - L284.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
The Vermont Oxford Network Steroid Study Group
Early Postnatal Dexamethasone Therapy for the Prevention of Chronic Lung Disease
Pediatrics, September 1, 2001; 108(3): 741 - 748.
[Abstract] [Full Text] [PDF]

Home page
 J Biomater ApplHome page
R. Banerjee and J. R. Bellare
Ultrastructure of Exogenous Surfactants Using Cryogenic Scanning Electron Microscopy
J Biomater Appl, January 1, 2001; 15(3): 230 - 240.
[Abstract] [PDF]

Home page
 J Biomater ApplHome page
R. Banerjee, R. R. Puniyani, and J. R. Bellare
Analysis of Dynamic Surface Properties of Therapeutic Surfactants and Lung Phospholipids
J Biomater Appl, October 1, 2000; 15(2): 140 - 159.
[Abstract] [PDF]

Home page
 PediatricsHome page
D. K. Richardson, J. E. Gray, S. L. Gortmaker, D. A. Goldmann, D. M. Pursley, and M. C. McCormick
Declining Severity Adjusted Mortality: Evidence of Improving Neonatal Intensive Care
Pediatrics, October 1, 1998; 102(4): 893 - 899.
[Abstract] [Full Text] [PDF]

Home page
 Arch. Dis. Child. Fetal Neonatal Ed.Home page
H. L HALLIDAY and R. F SOLL
Timing of surfactant treatment
Arch. Dis. Child. Fetal Neonatal Ed., March 1, 1998; 78(2): 156F - 156.
[Full Text]

Home page
 Am. J. Respir. Crit. Care Med.Home page
F. J. WALTHER, J. HERNANDEZ-JUVIEL, R. BRUNI, and A. J. WARING
Spiking Survanta with Synthetic Surfactant Peptides Improves Oxygenation in Surfactant-deficient Rats
Am. J. Respir. Crit. Care Med., September 1, 1997; 156(3): 855 - 861.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
B. T. Bloom, J. Kattwinkel, R. T. Hall, P. M. Delmore, E. A. Egan, J. R. Trout, M. H. Malloy, D. R. Brown, I. R. Holzman, C. H. Coghill, et al.
Comparison of Infasurf (Calf Lung Surfactant Extract) to Survanta (Beractant) in the Treatment and Prevention of Respiratory Distress Syndrome
Pediatrics, July 1, 1997; 100(1): 31 - 38.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
M. L. Hudak, D. J. Martin, E. A. Egan, E. J. Matteson, J. Cummings, A. L. Jung, L. V. Kimberlin, R. L. Auten, A. A. Rosenberg, J. M. Asselin, et al.
A Multicenter Randomized Masked Comparison Trial of Synthetic Surfactant Versus Calf Lung Surfactant Extract in the Prevention of Neonatal Respiratory Distress Syndrome
Pediatrics, July 1, 1997; 100(1): 39 - 50.
[Abstract] [Full Text] [PDF]